Alnylam Pharmaceuticals Inc. (ALNY) reported a third-quarter loss of 22 cents per share, below the Zacks Consensus Estimate of 24 cents but wider than the year-ago loss of 7 cents. The higher loss in the quarter is attributable to higher stock based compensation and legal expenses.

Revenues for the quarter came in at $24.2 million as against $25.7 million in the year-ago quarter, down 5.8%. Research and development costs increased 5% to $23.2 million primarily because of increased costs for clinical and pre-clinical programs coupled with increased R&D headcount to support Alnylam’s alliances and development programs.    General and administrative expenses increased 56% to $10.7 million. The increase in general and administrative spend was primarily driven by higher professional service fees in association with business activities, primarily legal activities, coupled with increased stock based compensation expenses.   Alnylam exited the quarter with $453.5 million in cash, cash equivalents and marketable securities

...

IDTechEx, Cambridge, MA - October 29, 2009 - Dependence on increasingly troublesome oil supplies and rapid degradation of the environment provide every reason why electric cars, whether hybrid or pure electric, should now be adopted rapidly.

The Pharma division of SAFC, a member of the leading Life Science and High Technology company, Sigma-Aldrich Group (SIAL) has completed the expansion of its Carlsbad, California facility. The facility conducts contract-manufacturing services for SAFC’s late phase and commercial clients. The $12 million expansion project included the addition of two fully segregated viral product-manufacturing suites built to employ the latest in disposable bioreactor technologies. This is aimed to expand SAFC Pharma's biologics, viral vaccines and gene therapy manufacturing to commercial quantities.

SAFC Pharma's Carlsbad site specializes in the process development and manufacturing of viral vaccines and viral therapeutics − including a full menu of support services − from preclinical process and analytical development to final fill/finish and commercial bulk drug supplies. The new expansion, designed for multi-lot campaigns, includes dedicated cell expansion, bioreactor production, purification and cleanroom suites. The expansion will enable both 100-liter batch production in stirred tank bioreactors

...

Though Sanofi-Aventis have been talking about their big pharma plans, it was today when they announced about their new billion-dollar plans. The company today announced their plans to acquire France’s Fovea Pharmaceuticals and MA-based Merrimack Pharmaceuticals for around US$ 530 million. Sanofi-Aventis announced that are all ready and prepared to spend the mentioned amount to make sure they wrap up both the deals quickly.

France’s Fovea Pharmaceuticals is an eye-disease biotech and Merrimack Pharmaceuticals that is based in Cambridge, MA is an in-license antibody cancer program.  Sanofi-Aventis has clearly announced that they are willing to cash up to 15 billion euro to restructure the management and projects in pipeline and would like to commit up to US$ 542 million to swiftly complete the acquisition process and make their first impression in

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Wednesday September 23, 2009

DrStockPick.com Stock Report!

GENZ, PWRM, STEM, CTIC, PFE

**************************************************************

GENZ, Genzyme Corporation

GENZ is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 11,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion.

GENZ provided an update on its progress to restore supplies of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) for patients worldwide and revised its 2009 revenue guidance for these products. GENZ is now approximately half-way through the anticipated shortage period

...

Companies featured in this edition of the newsletter: CVM, ICLK, IMUC, ITUI, IWEB, MBCI, NXOI, OMCM, ONEZ, PHC, SRCO, SVUL, XCR

Markets closed moderately higher yet again this week, as mostly better than expected economic data helped stave off profit taking to leave most indices in positive territory on the week. All told, the Dow ended the week up 0.4%, closing at 9544, up 38 points, bringing its YTD gains to 8.7%. The Nasdaq also gained 0.4% on the week to close at 2028, bringing its yearly gains to 28.6%, while the S&P 500 gained 0.3% and the Russell 2000 lost 0.3%, bringing their yearly gains to 13.9% and 16.1% respectively.

Economic news was in focus yet again this week in the absence of any market driving earnings data, as new home sales for July rose at 9.6%, posting its strongest gains since 2005. This positive development coupled with

...

Companies featured in this edition of the newsletter: CVM, ICLK, IMUC, ITUI, IWEB, MBCI, NXOI, OMCM, ONEZ, PHC, SRCO, SVUL, XCR

Markets closed moderately higher yet again this week, as mostly better than expected economic data helped stave off profit taking to leave most indices in positive territory on the week. All told, the Dow ended the week up 0.4%, closing at 9544, up 38 points, bringing its YTD gains to 8.7%. The Nasdaq also gained 0.4% on the week to close at 2028, bringing its yearly gains to 28.6%, while the S&P 500 gained 0.3% and the Russell 2000 lost 0.3%, bringing their yearly gains to 13.9% and 16.1% respectively.

Economic news was in focus yet again this week in the absence of any market driving earnings data, as new home sales for July rose at 9.6%, posting its strongest gains since 2005. This positive development coupled with

...

Toyota Motors (TM) has revealed that it will close down the New United Motor Manufacturing, Inc. (NUMMI) plant in Fremont, California, which had been operated with General Motors since 1984. The move is a part of the company’s plan to reduce worldwide capacity by 700,000 to 1 million vehicles. NUMMI, opened by General Motors in 1962, was shut down in 1982 on the back of operational inefficiency. However, the plant was reopened two years later when it became a 50/50 joint venture between General Motors and Toyota. NUMMI was a remarkable joint venture in America’s as well as Toyota’s history. The joint venture taught Americans about the famous Japanese "lean manufacturing system" (focused on just-in-time delivery) through NUMMI, and Toyota took its first step in the U.S. using GM’s supply lines. NUMMI has produced Corolla and Tacoma for Toyota and Pontiac Vibe for GM. However, GM ...

DrStockPick.com Stock Report!

Tuesday August 25, 2009

**************************************************************

OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, announced today that their EDC tool, TrialMaster(TM), has been selected by Pleiad, Inc., a Cambridge, Massachusetts based Contract Research Organization (CRO) with European operations in the U.K., to provide eClinical services to its customers. Pleiad’s investment will provide it with the products and services to manage two upcoming studies investigating the use of ophthalmic medical devices. This partnership is expected to generate more than $1 million to OmniComm over the next few years. Pleiad has worked with the TrialMaster EDC tool since April 2008 under

...

With fear of stating the obvious,  I have returned from Greece and baring any unforseen events, regular services shall return at Alpha.Sources within the next few days. I am preparing a bumper piece on a the theoretical link between export dependency and ageing (very long and very wonkish!), so stay tuned.

Greece naturally was wonderful and although we lived close to Athens we were not affected by the fires which now, sadly, seems to be almost out of control.

I managed to thoroughly relax and did not even get to read up on that textbook I had brought. This I imagine is a good sign :). I did however read David Leavitt. I finished the Indian Clerk and Arkansas. Leavitt is an excellent writer and the Indian Cleark is a fabulous, if sometime very windy, tale whose characters are explored with an almost excessive hunger for detail by Leavitt.

The fact

...